Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. [PDF]
Ann Rheum Dis, 2017 To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions.This open-label extension study recruited patients with RA who had completed the 54-week, randomised, parallel ...
Yoo DH +14 more
europepmc +8 more sources
Frontiers in Pharmacology, 2022 Background: Many pediatric inflammatory bowel disease (IBD) patients are now using biosimilars of anti-tumor necrosis factor-α (TNF-α), with increasing trends in recent years.
Valeria Dipasquale +3 more
doaj +1 more source
Current status of biosimilars in the treatment of inflammatory bowel diseases [PDF]
Intestinal Research, 2016 Introduction of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very
Dong Il Park
doaj +1 more source
Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. [PDF]
, 2020 ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Bansback, Nick +8 more
core +1 more source
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients [PDF]
, 2021 Background: Switching from IFX originator to CT-P13 is safe; however, little data on immunogenicity exists. Research design and methods: Consecutive IBD patients on IFX originator were switched to CT-P13 and followed-up for 12 months.
Armuzzi, Alessandro +15 more
core +1 more source
Journal of Crohn's & Colitis, 2023 CT-P13 subcutaneous (SC) infliximab formulation was developed to provide patients with a convenient option for treatment. Previous studies have shown efficacy and safety of CT-P13 SC comparable to CT-P13 intravenous (IV) in inflammatory bowel ...
B. Sands +23 more
semanticscholar +1 more source
Journal of Crohn's & Colitis, 2023 CT-P13 subcutaneous (SC) infliximab formulation showed comparable efficacy and safety with CT-P13 intravenous (IV) infliximab in inflammatory bowel disease (IBD)1 and rheumatoid arthritis2.
J. Colombel +23 more
semanticscholar +1 more source
Letter: treatment with subcutaneous CT‐P13 in Crohn’s disease patients with intravenous infliximab failure [PDF]
Alimentary Pharmacology & Therapeutics, 2022 LINKED CONTENTThis article is linked to Hanzel et al papers.
Caron, Bénédicte +3 more
openaire +3 more sources
Long-Term Efficacy and Safety in Patients With Rheumatoid Arthritis Continuing on SB4 or Switching From Reference Etanercept to SB4 [PDF]
, 2017 Objectives: SB4 (Benepali, Brenzys) is a biosimilar of reference etanercept (ETN). In a randomised, double-blind, 52-week study, SB4 demonstrated comparable efficacy and safety to ETN in patients with rheumatoid arthritis (RA).
Anna Sylwestrzak +27 more
core +4 more sources
Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort [PDF]
, 2016 Background and Aims: Biosimilar infliximab CT-P13 is approved for all indications of the originator product in Europe. Prospective data on its efficacy, safety, and immunogenicity in inflammatory bowel diseases are lacking.
Balázs Szalay +24 more
core +3 more sources